College of Rheumatology criteria for 20% improvement (ACR20 criteria). Data was obtained from a comprehensive literature review using PubMed, Medline, and Cochrane library. Effi cacy values were obtained from published randomized clinical trials. A decision tree analyses was conducted followed by one-way and two-way sensitivity analyses. Costs and effi cacy values associated with therapeutic options were varied in the sensitivity analyses. RESULTS: The probability of achieving ACR20 response for ETAN MTX, ADAL MTX, INFL MTX, and MTX were 85.5%, 65.95%, 61.26%, and 39.94%, respectively. The probability of an adverse drug event occurrence for ETAN MTX, ADAL MTX, INFL MTX, and MTX were 14.0%, 6.5%, 7.9%, and 9.5%, respectively. The analysis revealed that ETAN MTX option was the most cost-effi cacious, with an annual cost of $52,369 to the patient. The annual cost savings with ETAN MTX combination use would be $19,318. Annual costs of ADAL MTX, INFL MTX, and MTX monotherapy were $79,058, $68,932, and $67,071 respectively. Results were robust to both one-way and two-way analysis. OBJECTIVES: An observational study comparing risedronate to alendronate (REAL) in a subgroup of postmenopausal osteoporotic (PMO) women with prior fracture demonstrated that treatment with risedronate reduced the incidence of hip fracture by 66% in the fi rst year of treatment (Delmas, 2008). The objective of this analysis was to determine the cost-effectiveness of risedronate compared to alendronate at generic pricing using these effectiveness data in a high risk PMO population in the U.S. METHODS: A validated Markov model of osteoporosis (Tosteson, 2001) was used to estimate the impact of therapy on hip fractures, costs, and quality-adjusted life years (QALYs). The model simulated a cohort of 1000 women ages 65 with BMD 2.5 and a previous vertebral fracture, treated with risedronate or alendronate for one year. Associated costs and QALYs were tracked for an additional two years in each arm. Hip fracture incidence and mortality rates, as well as drug (generic alendronate 93.5% lower than risedronate) and hip fracture costs were extracted from published literature. RESULTS: In a cohort of 1000 women treated with risedronate versus alendronate, the model predicted 25 fewer hip fractures and 8.41 additional QALYs, resulting in a cost savings of $330,378. Extrapolating to a population of PMO women with a prior vertebral fracture in the U.S. suggests that risedronate prevents over 114,000 fractures in roughly 4.6 million women at cost savings of over $1,515 million. A sensitivity analysis assuming treatment for 2 years and parity effi cacy in year 2 resulted in a cost per QALY gained for earlier fracture protection of $9925 (cost per fracture averted: $3419) when treating with risedronate versus alendronate in the population 65 . Risedronate remains cost-saving in the 80 population. CON-CLUSIONS: Based on "real world" data this analysis suggests risedronate's early fracture protection results in favorable cost-effectiveness versus generic alendronate despite its higher drug cost.
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COST-EFFECTIVENESS IN OSTEOARTHRITIS PAIN RELIEF TREATMENT WITH NSAIDS -A DETERMINATION AND ESTIMATION OF KEY DRIVERS
Svedbom A 1 , Borgstrom F 1 , Holmstrom S 2 , Miltenburger C 3 1 i3 Innovus, Stockholm, Sweden, 2 NicOx, Sophia Antipolis, France, 3 i3 Innovus, Berlin, Germany OBJECTIVES: To determine and quantify the key drivers of cost-effectiveness in osteoarthritis (OA) treatment with traditional NSAIDs and COX-2 selective pharmaceuticals. METHODS: Cost effectiveness analysis (CEA) in OA treatment with traditional NSAIDs and COX-2 selective pharmaceuticals focus on side effects given the non-signifi cant differences in effi cacy (pain relief) among treatments. The most frequently included side-effects and complications in OA CEA analysis are gastrointestinal (GI) complications and myocardial infarction (MI). Given the concern about broader cardiovascular (CV) risks associated with NSAID treatment, the scope of a recently published Markov model (fi ve-year horizon, three-month cycles, health care perspective) was expanded to include four additional CV events (stroke, coronary insuffi ciency, venous thromboembolism and angina). Two treatments priced at 1) the average of celecoxib and etoricoxib, and 2) ibuprofen were evaluated. The model was populated with UK data. Absolute and relative GI risks were derived from a recent NICE HTA report whereas absolute CV risks were assumed to equal the normal population risk and relative CV risks were taken from the literature. The model was used to determine the most important drivers of cost-effectiveness in OA treatment. This was done by evaluating the responsiveness of the ICER to a 1% change in the input variable of interest, controlling for changes in all other variables. RESULTS: The fi ve most infl uential variables were (% impact on ICER resulting from 1% change in the variable): Quality of life in arthritis (2.5%), relative risk of CV events (1.5%), relative risk of mild GI events (1.3%), price of the COX-2 pharmaceutical (1.3%) and quality of life in dyspepsia (0.7%). CONCLUSIONS: Whilst the most important cost-effectiveness driver in OA treatment is overall quality of life changes, the analysis indicate that there might be higher economic benefi ts associated with decreasing CV risks rather than decreasing aspects of GI risk. OBJECTIVES: Injection site reactions (ISR) are the most common type of adverse event associated with the subcutaneous use of the tumor necrosis factor inhibitor (Anti-TNF) agents, etanercept (Enbrel) and adalimumab (Humira). The purpose of this study was to 1) investigate the incidence and characteristics of ISR, and 2) capture the humanistic and economic consequences of ISR in patients who received etanercept and/or adalimumab for rheumatoid arthritis (RA). METHODS: RA patients were identifi ed through a query of outpatient claims with an ICD-9 code for RA and practice code for Jefferson Rheumatology Associates, Philadelphia, PA. Patients who met inclusion criteria of 18 years old and having received etanercept or adalimumab in the past 3 years were administered a one-time observational survey developed by the investigators. RESULTS: The study included thirty patients, fi ve of which had used both adalimumab and etanercept. The overall prevalence of ISR was 56.3% (9 patients, n 16) for adalimumab and 84.2% (16 patients, n 19) for etanercept. Clinical characteristics of ISR included erythema (44.4%-68.8%), pruritus (44.4%-68.8%), and swelling (33.3%-56.3%). Only one patient (3.3%) in the cohort was pre-medicated for ISR. Three patients in the adalimumab (n 9, 33.3%) and one patient in the etanercept group (n 16, 6.25%) called their physician when experiencing a fi rst-time ISR. Ice was the most common form of treatment for the fi rst, typical, and worst incidence of ISR. No patients reported going to the ER, taking antihistamines, or using analgesics to treat ISR. Two patients (22.2%) and no patients discontinued therapy due to ISR in the adalimumab and etanercept group, respectively. No missed work-days were reported in either group due to ISR. CONCLUSIONS: ISR occurred in over half of the patient cases studied, and was largely characterized by erythema, pruritis, and swelling. Patient counseling about ISR is essential since selftreatment is common and discontinuation may result.
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